

Sydney Working Group Meeting Agenda

<https://join.freeconferencecall.com/pharmacy8>

Day	Date	AM /PM	Session	Agenda	Chair	Scribe	Co-Chair Availability	Room
Sunday	February 2, 2020	AM	Q1	Not Meeting				
		AM	Q2	Not Meeting				
		AM	Q3	Not Meeting				
		AM	Q4	Not Meeting				
Monday	February 3, 2020	AM	Q1	Not Meeting				
		AM	Q2	Not Meeting				
		PM	Q3	Not Meeting				
		PM	Q4	Not Meeting				
Tuesday	February 4, 2020	AM	Q1	Meeting <ul style="list-style-type: none"> Review Agenda Reps to other WGs <ul style="list-style-type: none"> Wed Q2 - O&O - HealthcareProduct: Substance, Substance Definition, BiologicallyDerivedProduct, Supply, Medication, MedicinalProduct, MedicationKnowledge - Scott Wed Q4 - Public Health - confirmed with Public Health that there are no agenda topics Thurs Q3 - CDS - will cancel and all go to CDS Fri Q1 - Patient Care - Care Plan report out - Scott Assign Roles for Quarters Approval of September 2019 WGM Minutes If we have new attendees, review <ul style="list-style-type: none"> Overview of Pharmacy material - V2, V3, FHIR Overview of Template work Hot Topics Prep for Joint FHIR meeting 	Jean	Melva	Melva Jean Scott	E3.3
		AM	Q2	Meeting <ul style="list-style-type: none"> Specialty Medication Prescribing PSS FHIR Trackers 	Melva	Scott	Melva Scott	E3.3
		AM	Q3	Meeting <ul style="list-style-type: none"> FHIR Trackers https://join.freeconferencecall.com/pharmacy8 	Scott	Melva	Melva Jean Scott	E3.3
		PM	Q4	Meeting <ul style="list-style-type: none"> Discuss Medication List with Michelle Miller 	Melva	Jean	Melva Scott Jean	E3.3
Wednesday	February 5, 2020	AM	Q1	Not Meeting				
		AM	Q2	Not Meeting - Rep to O&O				
		PM	Q3	Not Meeting				
		PM	Q4	Not Meeting				
Thursday	February 6, 2020	AM	Q1	Meeting <ul style="list-style-type: none"> Medication List Project 	Melva	Jean	Jean Melva ? Scott	C3.5
		AM	Q2	Meeting <ul style="list-style-type: none"> Medication List Project 	Scott	Melva	Jean Melva Scott	C3.5
		PM	Q3	Not Meeting - CANCELLED				

		PM	Q4	<p>Meeting</p> <ul style="list-style-type: none"> VA Pharmacy Project - Jay Lyle (material to be provided) <ul style="list-style-type: none"> Questions: <ul style="list-style-type: none"> Do these maps make sense? Are there assumptions I'm missing? Are there better approaches? Are there changes coming that might affect our approach? What other stakeholders would be interested in comparing extensions? What's the best channel for that discussion? Attachments: <ul style="list-style-type: none"> VAPharmaMaps.xlsx <ul style="list-style-type: none"> Notes: <ul style="list-style-type: none"> Columns A-J are VistA metadata. K-R are the proposed design description. There's a legend for the column headers. The areas of most interest will be the orders in the area (B) column: <ul style="list-style-type: none"> Inpatient Orders - pending/non-verified Inpatient Orders IV/Clinic Infusions Inpatient Orders Unit Dose/Clinic Medications Outpatient Orders Outpatient Orders - pending Non-VA Medications DD19_20191122_1155_JayLyle_BalancingActExposingLegacyDataInFHIR.pptx <ul style="list-style-type: none"> I also attach a slide deck for a high-level overview of what's going on in there, for what it's worth, which you can read or I can present, or both. 	Melva	Scott	Melva Scott	C3.5
Friday	February 7, 2020	AM	Q1	<p>Meeting - Rep to Patient Care</p> <p>Project Management</p> <ul style="list-style-type: none"> Schedule for Conference calls DMP - 2018 M&C - 2018 SWOT - 2018 Reaffirmation/Withdrawal of 5 year items <ul style="list-style-type: none"> PBS_Metrics_20190909.xlsx Forward Planning Project Review <ul style="list-style-type: none"> 3 year plan review Action Item list review Addition of another chair WGM Meeting planning <ul style="list-style-type: none"> CDS - Wednesday Q3 - do we want to do full joint or just send reps BR&R - Monday Q3 - will join BR&R FHIR-1 	Melva	Melva	Jean Melva	E3.5
		AM	Q2	Joint Meeting with FHIR-I - Pharmacy Hosting	Jean	Melva	Jean Melva Scott	E3.5
		PM	Q3	Not Meeting				
		PM	Q4	Not Meeting				